We next hypothesized that broadening the antitumor immune response with CBD-IL-12 therapy could improve the therapeutic efficacy of STEAP1-mBBζ CAR T cell therapy in prostate cancer by combating tumor antigen heterogeneity and rescue of antigen processing and presentation. Here, STEAP1 is linked to prostate cancer.